


Sexually Transmitted Infections MANAGEMENT GUIDELINES 2018

Adapted from: Standard Treatment Guidelines and Essential Medicine List PHC



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



PHC Chapter 12: Sexually transmitted infections

12.1	Vaginal discharge syndrome (VDS)	5
	12.1.1 Sexually non-active women	5
	12.1.2 Sexually active women	6
12.2	Lower abdominal pain (LAP)	7
12.3	Male urethritis syndrome (MUS)	8
12.4	Scrotal swelling (SSW)	9
12.5	Genital ulcer syndrome (GUS)	10
12.6	Bubo	11
12.7	Balanitis/ balanoposthitis (BAL)	12
12.8	Syphilis serology and treatment	13
12.9	Syphilis in pregnancy	16
12.10	Neonatal conjunctivitis	17
12.11	Treatment of more than one STI syndrome	18
12.12	Treatment of partners	19
12.13	Genital molluscum contagiosum (MC)	20
12.14	Genital warts (GW) Condylomata Accumunita	20
12.15	Pubic Lice (PL)	20

The syndromic approach to Sexually Transmitted Infections (STIs) diagnosis and management is to treat the signs or symptoms (syndrome) of a group of diseases rather than treating a specific disease. This allows for the treatment of one or more conditions that often occur at the same time and has been accepted as the management of choice.

Causative organisms and medicine management for STI syndromes:

ORGANISM	SYNDROME/S	MEDICINE MANAGEMENT
<i>Neisseria gonorrhoeae</i>	VDS, MUS, LAP	ceftriaxone + azithromycin <div style="border: 1px solid black; padding: 2px; display: inline-block;">LoE:III^r</div>
<i>Chlamydia trachomatis</i>	VDS, MUS, LAP, GUS, Bubo	azithromycin
<i>Trichomonas vaginalis</i>	VDS, LAP	metronidazole
<i>Bacterial vaginosis</i> (overgrowth of <i>Gardnerella vaginalis</i> , lactobacillus, anaerobes etc.)	VDS	metronidazole
<i>Candida albicans</i>	VDS	clotrimazole
<i>Treponema pallidum</i>	GUS	doxycycline/ benzathine benzylpenicillin
<i>Herpes simplex</i>	GUS	aciclovir
<i>Haemophilus ducreyi</i>	GUS, Bubo	azithromycin

It is important to take a good sexual history and undertake a thorough anogenital examination in order to perform a proper clinical assessment. The history should include questions concerning symptoms, recent sexual history, sexual orientation, type of sexual activity (oral, vaginal, anal sex), the possibility of pregnancy (females), use of contraceptives including condoms, recent antibiotic history, antibiotic allergy, recent overseas travel and domestic violence. Refer to a social worker, as required.

Note: Standard referral letter for treatment failure must include the following:

- » reason for referral: presumptive diagnosis (e.g. persistent cervicitis with suspected resistant gonorrhoea)
- » clinical findings including speculum examination for vaginal discharge
- » treatment history (including all medicines with dose and duration)
- » details of notification and treatment history of partner(s)

Suspected STI in children should be referred to hospital for further investigation and management.

GENERAL MEASURES

- » **Counselling and education, including HIV testing.**
- » **Condom promotion, provision and demonstration to reduce the risk of STIs.**
- » **Compliance/ adherence with treatment.**
- » **Contact treatment/ partner management.**
- » **Circumcision promotion (counselling to continue condom use).**
- » **Cervical cancer screening.**

Promote HIV counselling and testing.

For negative test results repeat test after 6 weeks, because of the window period.


Benzathine benzylpenicillin

Benzathine benzylpenicillin remains the recommended treatment for syphilis. However, due to global shortage of benzathine benzylpenicillin (limited global supply of the active pharmaceutical ingredient) the algorithms now recommend doxycycline, oral except in pregnant women and children. Azithromycin is not recommended for the treatment of syphilis in pregnancy as azithromycin does not effectively treat syphilis in the fetus, and resistance develops rapidly to macrolides. Therefore, the limited stock of benzathine benzylpenicillin must be reserved for use in pregnant women and children.


12.1 VAGINAL DISCHARGE SYNDROME (VDS)

B37.3/N76.0/N89.8

12.1.1 SEXUALLY NON-ACTIVE WOMEN

LoE:III²

12.1.2 SEXUALLY ACTIVE WOMEN



*People who are severely allergic to penicillin may also react to ceftriaxone.
If severe penicillin allergy, i.e. angioedema, anaphylactic shock or bronchospasm, omit ceftriaxone and increase azithromycin dose to:

- Azithromycin, oral, 2 g, as a single dose.


For ceftriaxone IM injection: Dissolve 250 mg in 0.9 mL lidocaine 1% without epinephrine (adrenaline).

Note:

- Do a speculum examination in all patients presenting with VDS.
- Pap smear should be taken after treatment, according to screening guidelines.
- Suspected STI in children should be referred to hospital for further management.


12.2 LOWER ABDOMINAL PAIN (LAP)

N73.9



12.3 MALE URETHRITIS SYNDROME (MUS)

A64 + N34.1



12.4 SCROTAL SWELLING (SSW)

N45.1



*If severe penicillin allergy, i.e. angioedema, anaphylactic shock or bronchospasm, omit ceftriaxone and increase azithromycin dose to:


- **Azithromycin**, oral, 2 g as a single dose.

For **ceftriaxone IM injection**: dissolve **250 mg** in 0.9 mL lidocaine 1% without epinephrine (adrenaline).

LoE:III^a

12.5 GENITAL ULCER SYNDROME (GUS)

A60.9/A51.0



*Penicillin allergic pregnant women: refer for confirmation of new syphilis infection and possible penicillin desensitisation.

**For benzathine benzylpenicillin, IM, 2.4 MU: Dissolve benzathine benzylpenicillin 2.4 MU in 6 mL lidocaine 1% without epinephrine (adrenaline).


*** 6-month follow-up RPR required of early syphilis cases treated with doxycycline OR amoxicillin + probenecid.

Note: Pregnant women presenting with genital ulcer(s) in the third trimester should be referred (risk of neonatal herpes).

LoE: I^B


12.6 BUBO

A58



12.7 BALANITIS/BALANOPOSTHITIS (BAL)

N48.1



12.8 SYPHILIS SEROLOGY AND TREATMENT

A53.9

Syphilis serology

The Rapid Plasmin Reagin (RPR) measures disease activity, but is not specific for syphilis. False RPR-positive reactions may occur, notably in patients with connective tissue disorders (false positive reactions are usually low titre <1:8). For this reason, positive RPR results should be confirmed due to syphilis by further testing of the serum with a specific treponemal test, e.g.:

- » *Treponema pallidum* haemagglutination (TPHA) assay.
- » *Treponema pallidum* particle agglutination (TPPA) assay.
- » Fluorescent Treponemal Antibody (FTA) assay.
- » *Treponema pallidum* ELISA.
- » Rapid treponemal antibody test (TPAb)

Screening can also be done the other way around starting with a specific treponemal test followed by a RPR in patients who have a positive specific treponemal test. This is sometimes referred to as the “reverse algorithm”.

- Once positive, specific treponemal tests generally remain positive for life and therefore the presence of specific treponemal antibodies cannot differentiate between current and past infections
- A person with previously successfully treated syphilis will retain lifelong positive specific treponemal test results.

The RPR can be used:

- » To determine if the patient’s syphilis disease is active or not,
- » To measure a successful response to therapy (at least a fourfold reduction in titre, e.g. 1:256 improving to 1:64), or
- » To determine a new re-infection.


Some patients, even with successful treatment for syphilis, may retain life-long positive RPR results at low titres ($\leq 1:8$), which do not change by more than one dilution difference (up or down) over time (so-called serofast patients).

Note:

- » Up to 30% of early primary syphilis cases, i.e. those with genital ulcers may have a negative RPR.
- » The RPR is always positive in the secondary syphilis stage and remains high during the first two (infectious) years of syphilis.

LoE:II^r

Perform RPR if indicated:
 » sexual assault case
 » suspected secondary syphilis
 » suspected tertiary syphilis
 » 6-month follow-up of syphilis cases treated with doxycycline OR amoxicillin + probenecid



Penicillin-allergic pregnant women:
 Refer for penicillin desensitisation.

***Early syphilis treatment:**
Severe penicillin allergy or benzathine benzylpenicillin is unavailable:
 • **Doxycycline**, oral, 100 mg 12 hourly for 14 days.

Pregnant or benzathine benzylpenicillin is unavailable:
 • **Amoxicillin**, oral, 1 g 8 hourly for 14 days
AND
 • **Probenecid**, oral 250 mg 8 hourly for 14 days.

****Latent/ late latent syphilis treatment:**
Severe penicillin allergy or benzathine benzylpenicillin is unavailable:
 • **Doxycycline**, oral, 100 mg 12 hourly for 30 days.

Pregnant or benzathine benzylpenicillin is unavailable:
 • **Amoxicillin**, oral, 1 g 8 hourly for 28 days
AND
 • **Probenecid**, oral 250 mg 8 hourly for 28 days.

For benzathine benzylpenicillin, IM, 2.4 MU: Dissolve 2.4 MU in 6 mL lidocaine 1% without epinephrine (adrenaline).

MEDICINE TREATMENT**Early syphilis treatment**

Check if treated at initial visit.

- Benzathine benzylpenicillin, IM, 2.4 MU immediately as a single dose.
 - Dissolve benzathine benzylpenicillin, IM, 2.4 MU in 6 mL lidocaine 1% without adrenaline (epinephrine).

In penicillin-allergic patients or if benzathine benzylpenicillin is unavailable: (Z88.0)

- Doxycycline, oral, 100 mg 12 hourly for 14 days.

LoE:III⁰

If pregnant and benzathine benzylpenicillin is unavailable:

- Amoxicillin, oral 1 g 8 hourly for 14 days (Doctor initiated).

AND

- Probenecid, oral 250 mg, 8 hourly for 14 days (Doctor initiated).

LoE:III⁰

If penicillin-allergic and pregnant: Refer for penicillin desensitisation.

Late/ late latent syphilis treatment

Check if treatment was commenced at initial visit.

- Benzathine benzylpenicillin, IM, 2.4 MU once weekly for 3 weeks.
 - Dissolve benzathine benzylpenicillin, IM, 2.4 MU in 6 mL lidocaine 1% without adrenaline (epinephrine).

In penicillin-allergic patients or if benzathine benzylpenicillin is unavailable: (Z88.0)

- Doxycycline, oral, 100 mg 12 hourly for 30 days.

LoE:III⁰

If pregnant and benzathine benzylpenicillin is unavailable:

- Amoxicillin, oral 1 g 8 hourly for 28 days (Doctor initiated).

AND

- Probenecid, oral 250 mg, 8 hourly for 28 days (Doctor initiated).


LoE:III¹

If penicillin-allergic and pregnant: Refer for penicillin desensitisation.


REFERRAL

- » Tertiary syphilis: neurosyphilis, cardiovascular syphilis; gummatous syphilis.
- » Clinical congenital syphilis.

12.9 SYPHILIS IN PREGNANCY



12.10 NEONATAL CONJUNCTIVITIS



12.11 TREATMENT OF MORE THAN ONE STI SYNDROME

STI SYNDROMES	TREATMENT (NEW EPISODE)
MUS + SSW	Treat according to SSW flow chart.
MUS + BAL	Treat according to MUS flow chart. AND • Clotrimazole cream, 12 hourly for 7 days.
MUS + GUS	• Ceftriaxone, IM, 250 mg immediately as a single dose. AND • Azithromycin, oral, 1 g as a single dose. AND • Aciclovir, oral, 400 mg 8 hourly for 7 days*.
VDS + LAP	Treat according to LAP flow chart. AND Treat for candidiasis, if required (see VDS flow chart).
VDS + GUS	• Ceftriaxone, IM, 250 mg immediately as a single dose. AND • Metronidazole, oral, 2 g immediately as a single dose. AND • Azithromycin, oral, 1 g as a single dose. AND • Aciclovir, oral, 400 mg 8 hourly for 7 days*. AND Treat for candidiasis, if required (see VDS flow chart).
LAP+ GUS	• Ceftriaxone, IM, 250 mg immediately as a single dose. AND • Metronidazole, oral, 400 mg 12 hourly for 7days. AND • Aciclovir, oral, 400 mg 8 hourly for 7 days*. AND • Azithromycin, oral, 1 g as a single dose.
SSW+ GUS	• Ceftriaxone, IM, 250 mg immediately as a single dose. AND • Aciclovir, oral, 400 mg 8 hourly for 7 days*. AND •
<p>*Treat with aciclovir only if HIV status is positive or unknown.</p> <p>**Penicillin allergic men and non-pregnant women avoid ceftriaxone and refer to relevant algorithms.</p> <p>Penicillin allergic pregnant/ breastfeeding women, refer for penicillin desensitisation.</p>	

12.12 TREATMENT OF PARTNERS

Syn-drome	Asymptomatic partner	Symptomatic partner
VDS	<ul style="list-style-type: none"> Ceftriaxone, IM, 250 mg immediately as a single dose. AND <ul style="list-style-type: none"> Metronidazole, oral, 2 g immediately as a single dose. AND <ul style="list-style-type: none"> Azithromycin, oral, 1 g as a single dose. 	<ul style="list-style-type: none"> Ceftriaxone, IM, 250 mg immediately as a single dose. AND <ul style="list-style-type: none"> Metronidazole, oral, 2 g immediately as a single dose. AND <ul style="list-style-type: none"> Azithromycin, oral, 1 g as a single dose. PLUS treatment for syndrome present if not included in the above.
LAP	<ul style="list-style-type: none"> Ceftriaxone, IM, 250 mg immediately as a single dose. AND <ul style="list-style-type: none"> Metronidazole, oral, 2 g immediately as a single dose. AND <ul style="list-style-type: none"> Azithromycin, oral, 1 g as a single dose. 	<ul style="list-style-type: none"> Ceftriaxone, IM, 250 mg immediately as a single dose. AND <ul style="list-style-type: none"> Metronidazole, oral, 2 g immediately as a single dose. AND <ul style="list-style-type: none"> Azithromycin, oral, 1 g as a single dose. PLUS treatment for syndrome present if not included in the above.
MUS	<ul style="list-style-type: none"> Ceftriaxone, IM, 250 mg immediately as a single dose. AND <ul style="list-style-type: none"> Azithromycin, oral, 1 g as a single dose. 	<ul style="list-style-type: none"> Ceftriaxone, IM, 250 mg immediately as a single dose. AND <ul style="list-style-type: none"> Azithromycin, oral, 1 g as a single dose. PLUS treatment for syndrome present if not included in the above (see VDS flow chart).
Scrotal swelling	<ul style="list-style-type: none"> Ceftriaxone, IM, 250 mg immediately as a single dose. AND <ul style="list-style-type: none"> Azithromycin, oral, 1 g as a single dose. 	<ul style="list-style-type: none"> Ceftriaxone, IM, 250 mg immediately as a single dose. AND <ul style="list-style-type: none"> Azithromycin, oral, 1 g as a single dose. PLUS treatment for syndrome present if not included in the above.
GUS	<ul style="list-style-type: none"> Doxycycline, oral, 100 mg 12 hourly for 14 days. <u>Except pregnant women:</u> <ul style="list-style-type: none"> Benzathine benzylpenicillin, IM, 2.4 MU immediately as a single dose. <ul style="list-style-type: none"> Dissolve benzathine benzylpenicillin, IM, 2.4 MU in 6 mL lidocaine 1% without epinephrine (adrenaline). (If pregnant and benzathine benzylpenicillin is unavailable, see syphilis flow chart).	<ul style="list-style-type: none"> Doxycycline, oral, 100 mg 12 hourly for 14 days. <u>Except pregnant women:</u> <ul style="list-style-type: none"> Benzathine benzylpenicillin, IM, 2.4 MU immediately as a single dose. <ul style="list-style-type: none"> Dissolve benzathine benzylpenicillin, IM, 2.4 MU in 6 mL lidocaine 1% without epinephrine (adrenaline). PLUS treatment for syndrome present if not included in the above. (If pregnant and benzathine benzylpenicillin is unavailable, see syphilis flow chart).
Bubo	<ul style="list-style-type: none"> Azithromycin, oral, 1 g as a single dose. 	<ul style="list-style-type: none"> Azithromycin, oral, 1 g as a single dose. PLUS treatment for syndrome present if not included in the above.

LoE:III²

12.13 GENITAL MOLLUSCUM CONTAGIOSUM (MC)

B08.1

DESCRIPTION

This is a viral infection which can be transmitted sexually and non-sexually. It is usually self-limiting but can be progressive in an advanced stage of immunodeficiency.

Clinical signs include papules at the genitals or other parts of the body. The papules usually have a central dent (umbilicated papules).

MEDICINE TREATMENT

- Tincture of iodine BP, topical.
 - Apply with an applicator to the core of the lesions.

12.14 GENITAL WARTS (GW): CONDYLOMATA ACCUMINATA

A63.0

DESCRIPTION

The clinical signs include:

- » Warts on the ano-genital areas, vagina, cervix, meatus or urethra.
- » Warts can be soft or hard.

In most cases, warts resolve without treatment after 2 years in non-immunosuppressed patients.

GENERAL MEASURES

- » If warts do not look typical or are fleshy or wet, perform a RPR test to exclude secondary syphilis, which may present with similar lesions.
- » Emphasise HIV testing.

REFERRAL

- » All patients with:
 - warts > 10 mm
 - inaccessible warts, e.g. intra-vaginal or cervical warts
 - numerous warts

12.15 PUBIC LICE (PL)

B85.3

DESCRIPTION

Infestation of lice mostly confined to pubic and peri-anal areas, and occasionally involves eyelashes.

The bites cause intense itching, which often results in scratching with bacterial super-infection.

GENERAL MEASURES

Thoroughly wash clothing and bed linen that may have been contaminated by the patient in the 2 days prior to the start of treatment in hot water and then iron.

MEDICINE TREATMENT

- Benzyl benzoate 25%
 - Apply to affected area.
 - Leave on for 24 hours, then wash thoroughly.
 - Repeat in 7 days.

Pediculosis of the eyelashes or eyebrows

- Yellow petroleum jelly (Note: Do not use white petroleum jelly near the eyes).
 - Apply to the eyelid margins (cover the eyelashes) daily for 10 days to smother lice and nits.
 - Do not apply to eyes.

LoE:III

REFERRAL

All children with lice on pubic, perianal area and eyelashes to exclude sexual abuse.

(Endnotes)

1 Ceftriaxone, IM (*Neisseria gonorrhoeae*): Lewis DA, Sriruttan C, Müller EE, Golparian D, Gumedé L, Fick D, de Wet J, Maseko V, Coetzee J, Unemo M. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant *Neisseria gonorrhoeae* infection in South Africa and association with cefixime treatment failure. *J Antimicrob Chemother.* 2013 Jun;68(6):1267-70. <https://www.ncbi.nlm.nih.gov/pubmed/23416957>

Ceftriaxone, IM (*Neisseria gonorrhoeae*): Lewis DA. Gonorrhoea resistance among men who have sex with men: what's oral sex got to do with it? *South Afr J Epidemiol Infect* 2013;28(2):77. https://journals.co.za/content/mp_sajei/28/2/EJC138699

2 Ceftriaxone, IM (*Neisseria gonorrhoeae*): Ito M, Yasuda M, Yokoi S, Ito S, Takahashi Y, Ishihara S, Maeda S, Deguchi T. Remarkable increase in central Japan in 2001-2002 of *Neisseria gonorrhoeae* isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones. *Antimicrob Agents Chemother.* 2004 Aug;48(8):3185-7. <https://www.ncbi.nlm.nih.gov/pubmed/15273147>

Ceftriaxone, IM (*Neisseria gonorrhoeae*): Tanaka M, Nakayama H, Tunoe H, Egashira T, Kanayama A, Saika T, Kobayashi I, Naito S. A remarkable reduction in the susceptibility of *Neisseria gonorrhoeae* isolates to cephems and the selection of antibiotic regimens for the single-dose treatment of gonococcal infection in Japan. *J Infect Chemother.* 2002 Mar;8(1):81-6. <https://www.ncbi.nlm.nih.gov/pubmed/11957125>

Ceftriaxone, IM (*Neisseria gonorrhoeae*): Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S,

Kubota Y, Tamaki M, Maeda S. Threat to cefixime treatment for gonorrhoea. *Emerg Infect Dis*. 2007 Aug;13(8):1275-7. <https://www.ncbi.nlm.nih.gov/pubmed/17953118>

Ceftriaxone, IM (Neisseria gonorrhoeae): Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhoea. *Future Microbiol*. 2012 Dec;7(12):1401-22. <https://www.ncbi.nlm.nih.gov/pubmed/23231489>

Ceftriaxone, IM (Neisseria gonorrhoeae): Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, Nicholas RA. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. *Antimicrob Agents Chemother*. 2009 Sep;53(9):3744-51. <https://www.ncbi.nlm.nih.gov/pubmed/19528266>

Ceftriaxone, IM (Neisseria gonorrhoeae): Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM.

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? *J Antimicrob Chemother*. 2010 Oct;65(10):2141-8. <https://www.ncbi.nlm.nih.gov/pubmed/20693173>

Ceftriaxone, IM (Neisseria gonorrhoeae): Contract circular RT301-2017: Ceftriaxone 250 mg, parenteral formulation.

Vaginal discharge syndrome – Sexual activity criterion: Kularatne R, Radebe F, Kufa-Chakezha T, Mbulawa Z, Lewis D. Sentinel Surveillance of Sexually Transmitted Infection Syndrome aetiologies and HPV genotypes among patients attending Primary Health Care Facilities in South Africa, April 2014 – September 2015. http://www.nicd.ac.za/wp-content/uploads/2017/03/3Final-25-April-2017_Revised-NAS_v5_NICD.pdf

Vaginal discharge syndrome – speculum examination: National Department of Health. Comprehensive STI Clinical Management Guidelines, draft version.

Clotrimazole, topical: Vaginal discharge syndrome – non-sexually active women (monotherapy syndromic directed management – candidiasis): Kularatne R, Radebe F, Kufa-Chakezha T, Mbulawa Z, Lewis D. Sentinel Surveillance of Sexually Transmitted Infection Syndrome aetiologies and HPV genotypes among patients attending Primary Health Care Facilities in South Africa, April 2014 – September 2015. http://www.nicd.ac.za/wp-content/uploads/2017/03/3Final-25-April-2017_Revised-NAS_v5_NICD.pdf

Metronidazole, oral: Vaginal discharge syndrome – non-sexually active women (monotherapy syndromic directed management – bacterial vaginosis): Kularatne R, Radebe F, Kufa-Chakezha T, Mbulawa Z, Lewis D. Sentinel Surveillance of Sexually Transmitted Infection Syndrome aetiologies and HPV genotypes among patients attending Primary Health Care Facilities in South Africa, April 2014 – September 2015. http://www.nicd.ac.za/wp-content/uploads/2017/03/3Final-25-April-2017_Revised-NAS_v5_NICD.pdf

3 Vaginal discharge syndrome – Sexual activity criterion: Kularatne R, Radebe F, Kufa-Chakezha T, Mbulawa Z, Lewis D. Sentinel Surveillance of Sexually Transmitted Infection Syndrome aetiologies and HPV genotypes among patients attending Primary Health Care Facilities in South Africa, April 2014 – September 2015. http://www.nicd.ac.za/wp-content/uploads/2017/03/3Final-25-April-2017_Revised-NAS_v5_NICD.pdf

Vaginal discharge syndrome – speculum examination: National Department of Health. Comprehensive STI Clinical Management Guidelines, draft version.

4 Doxycycline, oral (genital ulcer syndrome): World Health Organization. WHO guidelines

for the treatment of *Treponema pallidum* (syphilis), 2016. <http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf>

5 Benzathine benzylpenicillin (genital ulcer syndrome): Liu HY, Han Y, Chen XS, Bai L, Guo SP, Li L, Wu P, Yin YP. Comparison of efficacy of treatments for early syphilis: A systematic review and network meta-analysis of randomized controlled trials and observational studies. *PLoS One*. 2017 Jun 28;12(6):e0180001. <https://www.ncbi.nlm.nih.gov/pubmed/28658325>

Pregnant women, 1st trimester (genital ulcer syndrome): National Department of Health. Guidelines for Maternity Care in South Africa, 2016. <http://www.health.gov.za>

6 Azitromycin, oral (bubo): González-Beiras C, Marks M, Chen CY, Roberts S, Mitjà O. Epidemiology of *Haemophilus ducreyi* Infections. *Emerg Infect Dis*. 2016 Jan;22(1):1-8. <https://www.ncbi.nlm.nih.gov/pubmed/26694983>

7 Syphilis serology (RPR follow-up test in doxycycline-treated patients not recommended): Liu HY, Han Y, Chen XS, Bai L, Guo SP, Li L, Wu P, Yin YP. Comparison of efficacy of treatments for early syphilis: A systematic review and network meta-analysis of randomized controlled trials and observational studies. *PLoS One*. 2017 Jun 28;12(6):e0180001. <https://www.ncbi.nlm.nih.gov/pubmed/28658325>

Syphilis serology (RPR follow-up test in doxycycline-treated patients not recommended): Salado-Rasmussen K, Hoffmann S, Cowan S, Jensen JS, Benfield T, Gerstoft J, Katzenstein TL. Serological Response to Treatment of Syphilis with Doxycycline Compared with Penicillin in HIV-infected Individuals. *Acta Derm Venereol*. 2016 Aug 23;96(6):807-11. <https://www.ncbi.nlm.nih.gov/pubmed/26568359>

Syphilis serology (RPR follow-up test in doxycycline-treated patients not recommended): Dai T, Qu R, Liu J, Zhou P, Wang Q. Efficacy of Doxycycline in the Treatment of Syphilis. *Antimicrob Agents Chemother*. 2016 Dec 27;61(1). pii: e01092-16. <https://www.ncbi.nlm.nih.gov/pubmed/27795370>

8 Doxycycline, oral (Early syphilis treatment - penicillin allergic/benzathine benzylpenicillin unavailable): World Health Organization. WHO guidelines for the treatment of *Treponema pallidum* (syphilis), 2016. <http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf>

9 Amoxicillin, oral + probenecid, oral (Early syphilis treatment - pregnant/benzathine benzylpenicillin unavailable): Tanizaki R, Nishijima T, Aoki T, Teruya K, Kikuchi Y, Oka S, et al. High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection. *Clin Infect Dis*. 2015;61(2):177-83. <https://www.ncbi.nlm.nih.gov/pubmed/25829004>


Amoxicillin, oral + probenecid, oral (Early syphilis treatment - pregnant/benzathine benzylpenicillin unavailable): National Department of Health: Affordable Medicines, EDP-Adult Hospital level. Medicine Review: Amoxicillin+probenecid for syphilis in pregnant women, January 2018. <http://www.health.gov.za/>

10 Doxycycline, oral: Late latent syphilis treatment - penicillin allergic: World Health Organization. WHO guidelines for the treatment of *Treponema pallidum* (syphilis), 2016. <http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf>

11 Amoxicillin, oral + probenecid, oral (Late latent syphilis treatment - pregnant/benzathine benzylpenicillin unavailable): Tanizaki R, Nishijima T, Aoki T, Teruya K, Kikuchi Y, Oka S, et al. High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection. *Clin Infect Dis*. 2015;61(2):177-83. <https://www.ncbi.nlm.nih.gov/pubmed/25829004>

Amoxicillin, oral + probenecid, oral (Late latent syphilis treatment - pregnant/benzathine benzylpenicillin unavailable): National Department of Health: Affordable Medicines, EDP-Adult Hospital level. *Medicine Review: Amoxicillin+probenecid for syphilis in pregnant women*, January 2018. <http://www.health.gov.za/>

12 STI partner treatment: Centers for Disease Control and Prevention. 2015 Sexually Transmitted Diseases Treatment Guidelines. <https://www.cdc.gov/std/tg2015/>



Civitas Building, 222 Thabo Sehume St,
CBD, Pretoria, 0001

012 395 8000
<http://www.health.gov.za/>